Jiangbo Pharmaceuticals (ehem. GNPH) - A0RNJB/JGBO

Laiyang Pear Cough Syrup, Chinese Drug Approval Number Z37020940, helps relieve coughs arising from colds and other illnesses. Market feedback has shown that children like its fresh pear taste.

Baobaole Chewable Tablets, Chinese Drug Approval Number Z20070011, are a new product of Laiyang Jiangbo and entered the market in December 2007. Baobaole Chewable tablets are nonprescription drugs for gastric cavity aches. This drug stimulates the appetite and promotes digestion. Baobaole is used to cure deficiencies in the spleen and stomach, abdomen aches, loss of appetite, and loose bowels. Its effects are mild and lasting.

Since August 2007, we have develped a series of activities for the preparation of Baby Happy Chewable Tablests Launch, including a number of commercials we releasd on CCTV and SDTV, as well as nationwide distribution network building. Its revenue will be very favorable. The drug has since quickly gained its popularity in the market and the sales for this drug has grown at a fast pace since its initial introduction.

300 Aktien...lol

9 Dollar 10 cents...das ist eine Lachnummer...

12 Mill Outstanding shares...beim nächsten MOMO fliegt hier der Deckel weg bis mindestens 20$..es fehlt nur die Uplisting News !!

Eine unbekannte Perle...wird irgendwann wie RINO gehen von 10$ auf 35$ !!!!!!!!

Ich verwette meinen A....   :-)

im Gegensatz zu RINO hats hier nur 12 Millionen Aktien nicht 25Millionen oder mehr !!!
BAMM BAMM BAMM  .. es fehlen nur die News..aber wehe wenn...

JGBO unknown undiscovered Stock trading around CASH/share...

i am loading the boat here again... :-)


Momo kommt nächste Woche..versprochen !!!

Schön dass jemand merkt dass wir nahe am cash / aktie traden das ist ein WITZ...diese Aktie wird 40$++++ wert sein bei den richtigen News...BET YA !!!!!!!!!

JGBO just buy and hold this is a KABOOM STOCK...watch out !!!

 

uplisting hinter uns!

ax

jetzt willst du bashen??

Die News kommen und dann siehst du 40-50$ easy....

Glaub mir doch mal... :-)
Klappt doch sonst auch...

und die Aktie wird böse darunter leiden, weil dann Strafzahlungen fällig sind.

Ax ich kenn dich ja jetzt lange genug und ich weiss wie du tradest und jetzt sag mir mal wer KERX bei 0.30€ zum Kauf empfohlen hat :-)
Der gleiche Volltrottel hat zu 0.45€ verkauft und du hast geahlten bis heute...so ist das... :-)
Geh zurück in deine Höhle..billiger wird hier nicht mehr...BASTA !!!!!!!!!!

 

ax

In das rothaarige sTIEFKIND DER cHINA INVESTOREN...keiner mag es aber ich liebe es... :-)
Traded bei cash / share....billig bin ich drangekommen...bald werden es alle lieben... :-)

sehr bald einer der grossen pharma player in china...mit grossem Distributions Netzwerk...
Die vergessene Perle der Volksrepublik China...WUBO hat Super Kontakte zur Regierung...hier geht was !!!!!!!!!
Universität gekauft f> LALA

und welche die mich kennen wissen was das heisst...   (CNO SNSS KERX CYCC..usw..)    ja nicht verpassen !!! :-)

bei uplisting...120 in 3 Jahren....abwarten...

Diese Aktie kennt KEINER !!!!!   :-)

   

 

Wubo Cao
CEO&President
Mr. Cao, Chief Executive Officer, President and Chairman of Jiangbo Pharmaceuticals, Inc, also served as General Manager of Laiyang Jiangbo since 2003 with more than  20 years working experiences in pharmaceutical industry. Previously, from 1998 until 2003, he was General Manager of combined entity: Laiyang Jiangbo Pharmacy Co. Ltd. and Laiyang Jiangbo Chinese and Western Pharmacy Co. Ltd. From 1988 to 1998, he was working in Laiyang Yongkang Pharmaceutical factory as Marketing Manager continually. Prior to this, from 1981 to 1988, Mr. Cao completed his military service in Chinese Army, during which he was the President of sales in Laiyang Yongkang Pharmaceutical Factory.

Elsa Sung
CFO
Ms. Sung is the Chief Financial Officer for Jiangbo Pharmaceuticals, Inc.  She joined Jiangbo in October 2007. Ms. Sung served as Vice President of CFO Oncall, Inc. from July 2007 to June 2008.  Prior to joining CFO Oncall, Inc., Ms. Sung was an Audit Manager at Sherb & Co., Boca Raton, Florida, responsible for managing, monitoring, as well as performing audits for domestic and international clients.  Before joining Sherb & Co., Ms. Sung was a Senior Internal Auditor at Applica Consumer Products, Inc., a U.S. public traded company. Prior to this, Ms. Sung was with Ernst & Young, LLP in West Palm Beach, Florida as a Senior Auditor in the Assurance and Advisory Business Service Group. Ms. Sung is a licensed CPA in the State of Georgia and a member of the American Institute of Certified Public Accountants. She received her Master of Business Administration and Bachelor’s Degree, graduated “Cum Laude”, in Accounting from Florida Atlantic University. She also holds a Bachelor’s Degree in Sociology from National Chengchi University in Taipei, Taiwan.

Lining Dong
Vice President&Director of Technology

Mr. Dong, Vice President and Director of Technology for Jiangbo Pharmaceuticals, Inc, also served as the Deputy General Manager of Laiyang Jiangbo since July 2003, and also the Vice President and Director of Technology of the combined entity.  He was graduated from Shandong Pharmacy University in 1995. Prior to joining Jiangbo Pharmaceuticals,  from July 1986 to July 2003, Mr.Dong, a Licensed Pharmacist, worked in Laiyang Biochemistry Pharmaceutical factory, as a checker, associate engineer, workshop director, Head of product technology section, Deputy Director of technology factory. He has published several pharmaceutical thesis articles in magazines such as, Chinese Biochemical Medical Magazine, Food and Drug, and China New Clinical Medicine.



Weidong Yang
Vice President&Director of Sales

Mr. Yang is the Vice President and Director of Sales for Jiangbo Pharmaceuticals, Inc. Also, he has served as the Deputy General Manager of Laiyang Jiangbo since July 2003. Previously, from April 2000 to July 2004, he was area director in Jiangsu Jizhou Pharmaceutical Co. Ltd. Prior to this, from February 1995 to March 2000, he worked as sales director at Jiangsu Yangtze Pharmaceutical Co. Ltd.



Jingsheng Xin
Vice President&Director of Equipment

Mr. Xin is the Vice President and Director of Equipment Department of Jiangbo Pharmaceuticals, Inc, also served as the Deputy General Manager of Laiyang Jiangbo since October 2003. He was graduated from Chinese People’s Liberation Army Chongqing Wireless Engineering Technical Institute in 1978. Prior to joining Jiangbo Pharmaceuticals, Inc,He worked in Laiyang Construction Bureau from August 2001 to September 2003; Previously, Mr. Xin worked at Pharmaceuticals factory of Army 54685 from April 1983 to August 2001. He has been engaged in pharmaceutical industry for more than 20 years, and his varied experiences including positions as a Technician, Engineer Assistant, Engineer, Deputy Director, Director and Deputy General Manager. He participated in industrial training held by Chinese National Drug Supervising Department and Shandong Drug Supervising Department. Also, he is very familiar with laws and statutes about Chinese pharmaceutical industry.

Ms. Huang graduated from Kwantlen University College in Canada. She also earned her MBA degree from the University of British Columbia in 2006. From November 2006 to 2007, she was a marketing manager in CúC Top Enterprises Ltd. While a student, Ms. Huang has published articles on business administration at Canada Weekly and school magazines, and earned the Best International Student Scholarship and a full scholarship. Ms. Huang speaks English, French, Mandarin and Cantonese, and has a working knowledge of accountancy and business administration.

Jian Ge  

Mr. Ge graduated from Shandong University Management Sciences Department with a Bachelor of Business Administration in 1992. From 1992 to the end of 2000, he worked for the Development and Reform Commission of Yantai. From 2001 to 2006, he was the Minister of the Capital Operation Department and the Minister of the Development Department in Zhenghai Group Co. Ltd., and a director of Yantai Hualian Development Co., Ltd. Presently, he is General Manager and Director of Yantai Zhenghai Pawn Co.Ltd. Member of  our Compensation Committee.

Michael Marks

In January 2003, Mr. Marks founded the China practice of Sonnenblick Goldman, a New York headquartered real estate investment bank established in 1893, and until December 2007 served as China managing director and regional principal of the firm. Sonnenblick Goldman provides a full range of real estate financial services including debt and equity placements, joint ventures, investment sales and real estate advisory services. Since October 2007 Mr. Marks has served as an independent director of China Housing & Land Development, Inc. (CHLN:OTCBB), a developer of residential and commercial property in Shaanxi Province, China. During his eight-year tenure in China, Mr. Marks has served in an advisory role, either as a consultant or investment banker, in over $1.5 billion of transactions, and has worked closely with both international and Chinese institutions. These include,  inter alia , The Carlyle Group, Starwood Capital, Lehman Brothers, Goldman Sachs, Dubai Investment Group, Beijing International Trust and Investment Corporation, China Jin Mao Group Company Limited, and Shanghai Investment Group. In September 2002, Mr. Marks founded the Shanghai office of Horwath Asia Pacific, a hotel and tourism advisory firm affiliated with Horwath International, a global accounting and advisory firm. He serves as its director and Shanghai representative. From January 1998 to June 1999, Mr Marks served as a manager of Horwath Asia Pacific in Sydney, Australia. In March 2001, Mr. Marks founded B2Globe, a start-up business in the Asia-Pacific region focusing on outsourcing of systems design, payment processing, risk management, customer service, and marketing from international Internet businesses penetrating the Chinese-language markets in Asia. From March 2001 to August 2002, when B2Globe was sold, Mr. Marks served as its chief executive officer. In June 1999, Mr. Marks joined Metro Education in China and co-founded Metro Corporate Training in Shanghai, China as a joint venture partnership with a Chinese education and training institute, offering corporate training and management development solutions to executives of Chinese and international companies, professionals and students, and served as the group and company’s chief executive officer until February 2001. From June 1999 to November 2004, when a controlling interest in Metro Education was sold, Mr. Marks also served as a director of Metro Education. From January 1995 to January 1998, Mr. Marks worked in the audit, corporate finance and advisory divisions in the Johannesburg, South Africa office of Price Waterhouse. Mr. Marks graduated with a Bachelor of Commerce (Honors) and Masters of Commerce from the University of the Witwatersrand in Johannesburg, South Africa in 1994 and 1997 respectively. In 1998 Mr Marks graduated with a Bachelor of Arts (Psychology) degree from the University of South Africa. In 1997 Mr. Marks qualified as a Chartered Accountant in South Africa, and in 1999 as a Fellow of the Association of International Accountants in the United Kingdom. Since June 1999 Mr. Marks has lived in Shanghai, China. He speaks fluent Mandarin, French and English.Chairman of our Audit Committee

John (Yang) Wang

John (Yang) Wang has served as our director since September 8, 2008. Since November 2004, Mr. Wang has been the President of Marbella Capital Partners. Since September 2007, he also serves as the CEO of Hambrecht Asia Acquisition Corp., and is on the Board of Directors of Hong Kong Stock Exchange listed Wuyi International Pharmaceuticals Company Limited. From 2000 to 2004, he was Executive Vice President of SBI E2-Capital (HK) Limited. From 1997 to 1999, he managed Accenture Consulting’s (formerly known as Andersen Consulting) Greater China communication, media and high tech strategy practice. Prior to that, he was the lead telecom analyst covering Greater China and Southeast Asia for Pyramid Research, an emerging market telecom research firm based in Cambridge, Massachusetts. Mr. Wang holds a Bachelor of Arts in International Relations from Tufts University and an M.A.L.D. degree in international law and business from The Fletcher School of Law and Diplomacy. He has over 15 years of experience in investment banking and consulting and speaks fluent Mandarin and English. Member of our Audit Committee and our Compensation Committee.

Perf. seit Threadbeginn:   +54,05%


!!!!!!!!!!!!!!!!!!!!!!!!!

Und das hier sind wieder EINSTIEGSPREISE !!!!!!!
Wir waren schon bei weit mehr als 100% !!!!!!!!!!!

Der Ceo ist auch President bei Hilead...

www.china-hilead.com/en/index.asp

Hier ist der Spekulationsgedanke nah dass......??    :-)  (tüdeldüüü nix genaueres weiss man nicht)

• China, currently the world’s sixth-largest pharmaceutical market, will account for 21%
of global sales growth in the pharmaceutical industry through 2013, with projected
average annual growth of 40% through 2011. *
• By 2011, China should become the third-biggest prescription drug market — after the
U.S. and No. 2 Japan *

* IMS Health

images.investorshub.advfn.com/images/...nzwiJGBO_Products.JPG" style="max-width:560px" />

images.investorshub.advfn.com/images/...tkJGBO_Products_2.JPG" style="max-width:560px" />

images.investorshub.advfn.com/images/...zsJGBO_Products_3.JPG" style="max-width:560px" />

images.investorshub.advfn.com/images/...JGBO_Distribution.JPG" style="max-width:560px" />

CFO of Jiangbo Pharmaceuticals Gives Live Interview on Bloomberg TV Asia